1652.HK Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 birž. 2024 @ 10:38):
Our systems believe the stock currently is undervalued by 0.10% compare to its pairs and should correct upwards.

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China...

Stats
Šios dienos apimtis	235 000
Vidutinė apimtis	159 271
Rinkos kapitalizacija	722.68M
EPS	HKD-0.0352 ( Q4 \| 2023-12-31 )
Last Dividend	HKD0.00420 ( 2022-06-07 )
Next Dividend	HKD0 ( N/A )
P/E	-19.40 (Sector) 0 (Industry) 0
ATR14	HKD0.0300 (3.09%)

0013.HK -0.72%

0239.HK 1.24%

0455.HK 1.96%

0512.HK -0.21%

0570.HK 0.83%

0719.HK 0.75%

0858.HK 2.56%

0867.HK 0.76%

0874.HK 0.24%

0911.HK -1.75%

1011.HK -10.26%

1312.HK 3.03%

1349.HK 0.56%

1498.HK 0.00%

1513.HK 0.78%

1558.HK 5.15%

1652.HK -2.02%

1681.HK 2.58%

2161.HK 5.00%

2196.HK 0.46%

2552.HK 2.70%

2633.HK 1.56%

2877.HK -1.79%

3737.HK 0.00%

6185.HK 0.72%

6896.HK -0.65%

8049.HK -0.76%

8329.HK 3.62%

8622.HK 0.00%

9989.HK 2.52%

Koreliacija (AI algo v.1.1b): Undervalued: 0.10% HKD0.971 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Fusen Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Fusen Pharmaceutical Finansinės ataskaitos

Annual	2023
Pajamos:	HKD565.61M
Bruto pelnas:	HKD299.51M (52.95 %)
EPS:	HKD-0.0500

FY	2023
Pajamos:	HKD565.61M
Bruto pelnas:	HKD299.51M (52.95 %)
EPS:	HKD-0.0500

FY	2022
Pajamos:	HKD491.76M
Bruto pelnas:	HKD225.02M (45.76 %)
EPS:	HKD-0.0458

FY	2021
Pajamos:	HKD385.66M
Bruto pelnas:	HKD211.13M (54.75 %)
EPS:	HKD0.0210

Financial Reports:

No articles found.

Fusen Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Fusen Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.527 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	HKD0.00620	2018-09-13
Last Dividend	HKD0.00420	2022-06-07
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.0436	--
Avg. Dividend % Per Year	0.00%	--
Score	1.08	--
Div. Sustainability Score	1.527
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-08-30)

HKD0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

1.08

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
07 Jun 2022	HKD0.00420	30 Nov -0001	30 Nov -0001	30 Nov -0001
17 Sep 2021	HKD0.00680	30 Nov -0001	30 Nov -0001	30 Nov -0001
08 Jun 2021	HKD0.00540	30 Nov -0001	30 Nov -0001	30 Nov -0001
15 Sep 2020	HKD0.00510	30 Nov -0001	30 Nov -0001	30 Nov -0001
03 Jul 2020	HKD0.00400	31 Mar 2020	06 Jul 2020	10 Aug 2020
13 Sep 2019	HKD0.00330	30 Aug 2019	16 Sep 2019	29 Nov 2019
03 Jul 2019	HKD0.00860	29 Mar 2019	04 Jul 2019	09 Aug 2019
13 Sep 2018	HKD0.00620	31 Aug 2018	14 Sep 2018	30 Nov 2018

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2331.HK	Ex Dividend Knight	2023-08-23	Sporadic	0.00%
0595.HK	Ex Dividend Junior	2023-09-06	Annually	0.00%
1821.HK	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%
0163.HK	Ex Dividend Junior	2023-09-26	Semi-Annually	0.00%
9983.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
1268.HK	Ex Dividend Knight	2023-09-20	Semi-Annually	0.00%
3600.HK	Ex Dividend Knight	2023-09-12	Annually	0.00%
0817.HK	Ex Dividend Junior	2023-09-18	Semi-Annually	0.00%
2003.HK	Ex Dividend Junior	2023-10-17	Annually	0.00%
0375.HK	Ex Dividend Knight	2023-09-27	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0641	1.500	-1.283	-1.924	[0 - 0.5]
returnOnAssetsTTM	-0.0270	1.200	-0.900	-1.080	[0 - 0.3]
returnOnEquityTTM	-0.0612	1.500	-1.791	-2.69	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0.853	0.800	-0.735	-0.588	[1 - 3]
quickRatioTTM	0.329	0.800	-2.77	-2.22	[0.8 - 2.5]
cashRatioTTM	0.0524	1.500	-0.820	-1.230	[0.2 - 2]
debtRatioTTM	0.256	-1.500	5.73	-8.60	[0 - 0.6]
interestCoverageTTM	6.34	1.000	8.76	8.76	[3 - 30]
operatingCashFlowPerShareTTM	-0.0979	2.00	-0.0326	-0.0653	[0 - 30]
freeCashFlowPerShareTTM	-0.186	2.00	-0.0931	-0.186	[0 - 20]
debtEquityRatioTTM	0.611	-1.500	7.56	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.530	1.000	4.51	4.51	[0.2 - 0.8]
operatingProfitMarginTTM	0.0379	1.000	-1.241	-1.241	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.213	1.000	-2.30	-2.30	[0.2 - 2]
assetTurnoverTTM	0.421	0.800	-0.527	-0.422	[0.5 - 2]
Total Score				1.527

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-18.63	1.000	-1.983	0	[1 - 100]
returnOnEquityTTM	-0.0612	2.50	-1.151	-2.69	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.186	2.00	-0.0621	-0.186	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0979	2.00	-0.0326	-0.0653	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.943	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.130	1.000	-5.74	0	[0.1 - 0.5]
Total Score				-2.08

Fusen Pharmaceutical Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Fusen Pharmaceutical

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.